Allogene CFO Geoffrey Parker to retire effective Nov 6, 2026

Allogene Therapeutics, Inc.

Geoffrey Parker, EVP and CFO, notified company of retirement on Aug 31, 2026.
Retirement effective November 6, 2026; he will depart in all capacities.
No successor named in the filing; company has not announced a replacement.
Parker served as principal financial officer; transition period of ~2 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.